📰 Ucb Inc News
Ucb Inc News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ucb Inc. Real-time updates on events, politics, business and more.
May 2, 2024
Case Name: UCB, Inc. v. Mylan Techs. Inc., Civ. No. 22-cv-216 (D. Vt. Mar. 8, 2024) (Reiss, J.) - Drug Product and Patent(s)-in-Suit: Neupro® (rotigotine); U.S. Patents Nos. 8,246,979...
April 12, 2024
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology Annual Meeting Diverse and...
April 4, 2024
/PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the...
January 22, 2024
The products include Pilocarpine Hydrochloride Ophthalmic Solution 0.4%, Tenapanor, Zilucoplan, and Bimekizumab-bkzx.
January 3, 2024
ZILBRYSQ® is now commercially available by prescription in the United States and dispensed by UCBs selected exclusive specialty pharmacy PANTHERx® Rare Pharmacy.ZILBRYSQ is FDA-approved as the...
December 29, 2023
Case Name: UCB, Inc. v. Annora Pharma Priv. Ltd., Civ. No. 20-987-CFC, 2023 WL 5274566 (D. Del. Aug. 16, 2023) (Connolly, J.) - Drug Product and Patent(s)-in-Suit: Briviact®...
December 22, 2023
In Incept v. Palette Life Sciences 21-2063, 21-2065 (Fed. Cir. Aug. 16, 2023), the case addresses the Board’s anticipation and obviousness…
December 22, 2023
In Incept v. Palette Life Sciences 21-2063, 21-2065 (Fed. Cir. Aug. 16, 2023), the case addresses the Board’s anticipation and obviousness determinations in two IPRs (IPR2020-00002 and...
December 2, 2023
Study presents new persistence analysis of FINTEPLA, evaluating the efficacy and tolerability of FINTEPLA over a span of 12 months1 Real-world data looks into the need for resources to support caregivers – both parents and siblings – of people living with developmental and epileptic encephalopathies such as Dravet and Lennox-Gastaut syndromes in the transition from […]
December 1, 2023
UCB will present 29 abstracts, including 4 late breakers, at American Epilepsy Society Annual Meeting 2023 highlighting clinical, health economic and...